Results 91 to 100 of about 113,904,810 (178)

Repurposing the Neurokinin-1 receptor antagonist Aprepitant to eradicate relapsed/refractory acute lymphoblastic leukemia via mitochondria-driven necroptosis

Cancer Letters
The prognosis for relapsed/refractory acute lymphoblastic leukemia (R/R ALL) remains dismal due to intrinsic and acquired chemoresistance, highlighting an urgent need for novel therapeutic strategies. The neurokinin-1 receptor (NK-1R) represents an emerging oncological target, yet its role and therapeutic potential in ALL are incompletely understood ...
Gang Shao, Hanling Pan, Jiayi Zhu, Nanfang Zhuo, Xurui Cheng, Hongzhang Wu, Ruitao Xiao, Xiangyu Hong, Jianhu Li, Junjie Ma, Xiangmin Tong, Huafeng Wang, Xi Wang, Caiyun Fu   +13 more
openaire   +2 more sources

The neurokinin 1 receptor antagonist, ezlopitant, reduces appetitive responding for sucrose and ethanol. [PDF]

, 2010
The current obesity epidemic is thought to be partly driven by over-consumption of sugar-sweetened diets and soft drinks. Loss-of-control over eating and addiction to drugs of abuse share overlapping brain mechanisms including changes in motivational ...
Nielsen, CK, Jeffrey A Simms, Bito-Onon, JJ, Jade J. Bito-Onon, Bartlett, SE, Bito-Onon Jade J., Nielsen, Carsten, Holgate Joan, Bito-Onon, Jade, Steensland, P,, Jeffrey A. Simms, Selena E. Bartlett, Joan Holgate, Holgate, Joan, Bartlett, Selena, Carsten K Nielsen, Nielsen Carsten K., Bartlett Selena E., Pia Steensland, Simms Jeffrey A., Steensland, Pia, Carsten K. Nielsen, Holgate, J, Selena E Bartlett, Simms, JA, Jade J Bito-Onon, Steensland Pia, Simms, Jeffrey   +27 more
core   +2 more sources

Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK

Cancer Management and Research, 2013
Samantha Humphreys,1 James Pellissier,2 Alison Jones3 1Market Access Department, Merck Sharp and Dohme Ltd, Hoddesdon, Hertfordshire, UK; 2Health Economic Statistics, Merck Research Laboratories, Upper Gwynedd, PA, USA; 3Department of Medical Oncology ...
Humphreys S, Pellissier J, Jones A
doaj  

Comparison of aprepitant versus ondansetron for prevention of postoperative nausea and vomiting: A systematic review and meta-analysis with trial sequential analysis

Indian Journal of Anaesthesia
Background and Aims: Postoperative nausea and vomiting (PONV) is a common complication after surgery. Preventing PONV in high-risk patients often requires a multimodal approach combining antiemetic drugs with diverse mechanisms.
Madhusudan P. Singh, Meenalotchini P. Gurunthalingam, Ayushee Gupta, Juhi Singh   +3 more
doaj   +1 more source

Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant.

, 2009
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) belongs to the most feared side-effects of cancer treatment. Its incidence during chemotherapy of gastrointestinal tumors (GITs) with highly and moderately emetogenic regimens is not well ...
Abbrederis, Kathrin;Lorenzen, Sylvie;Rothling, Nadine;Ihbe-Heffinger, Angela;Schuster, Tibor;Peschel, Christian;Lordick, Florian, Abbrederis, K;Lorenzen, S;Rothling, N;Ihbe-Heffinger, A;Schuster, T;Peschel, C;Lordick, F   +1 more
core   +1 more source

Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy

, 2011
Background: The combination of a neurokinin-1 receptor antagonist, dexamethasone, and a 5-HT 3 receptor antagonist is currently the standard antiemetic treatment in patients receiving cisplatin-based high emetogenic chemotherapy (HEC).
Quadrini S., Grande R., De Luca C., Cortesi E., Gamucci T., De Sanctis R., Del Signore E., D'Antoni I., Di Seri M., Longo F., Stumbo L., Gori B., Mansueto G., Altavilla A., Cimadon B., Lapadula V.   +15 more
core   +2 more sources

Antileukemic effects of neurokinin-1 receptor inhibition on hematologic malignant cells: A novel therapeutic potential for aprepitant

, 2018
Genetic and laboratory studies have remodeled the conventional understanding of cancer pathogenesis by identifying different molecular alterations.
Safaroghli-Azar, A., Bashash, D., Safa, M., Bayati, S., Ghaffari, S.H., Razani, E.   +5 more
core  

Neurokinin-1 receptor antagonism, aprepitant, effectively diminishes post-operative nausea and vomiting while increasing analgesic tolerance in laparoscopic gynecological procedures [PDF]

, 2011
Purpose : Post-operative nausea and vomiting (PONV) remains the most frequently reported patient complaint after anesthesia. Aprepitant is the first neurokinin-1(NK1) receptor antagonism available for use as an antiemetic.
オオシタ, シュウゾウ, ホリカワ, ヨウスケ, カクタ, ナミ, 角田, 奈美, 木下, 倫子, ツツミ, ヤスオ, Horikawa, Yousuke T., 453, 454, カワノ, ヒロアキ, Tanaka, Katsuya, 1532, 大下, 修造, Kakuta, Nami, 60144945, 208068/profile-ja.html, 90523499, 田中, 克哉, タナカ, カツヤ, 00622606, Oshita, Shuzo, 堤, 保夫, 60045/profile-ja.html, 30263841, 河野, 裕明, キノシタ, ミチコ, 60304/profile-ja.html, 1645, 343, 208070/profile-ja.html, Kinoshita, Michiko, Kawano, Hiroaki, Tsutsumi, Yasuo   +32 more
core  

The safety and efficacy of aprepitant in combination with other antiemetic agents for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric patients

, 2016
Chemotherapy induced nausea and vomiting is the one of the most dreaded complication of chemotherapy in pediatric and adult cancers. Aprepitant is a neurokinin-1 antagonist that has shown significant efficacy in controlling acute and delayed chemotherapy
Batra, Atul, Bakhshi, Sameer
core   +1 more source

Equivalent Dynamic Human Brain NK1-Receptor Occupancy Following Single-Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging

, 2012
The type 1 neurokinin receptor (NK1R) antagonist aprepitant and its i.v. prodrug fosaprepitant have been approved for prevention of acute and delayed nausea and vomiting associated with chemotherapy.
Hargreaves, R.J., Koole, Michel, Butterfield, K.L., Mahon, C., Tatosian, D., Xie, W., Liu, Y., de Hoon, Jan, Zappacosta, P., Shadle, C.R., Wagner, J.A., De Lepeleire, I., Murphy, M.G., Hamill, T., Derdelinckx, Inge, Van Laere, Koen, Rosen, L.B., Mozley, P.D., Declercq, R., Sanabria Bohorquez, S.M., Bormans, Guy, Liu, F.   +21 more
core   +1 more source